Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RLYB

+ Watchlist+ Portfolio

Rallybio Corp.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$15.29
52-Week Range
$3.67 – $17.57
Market Cap
$85.46M
P/E (TTM)
3.31
EPS (TTM)
4.61
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.88
PEG Ratio
—
Return on Equity
34.52%
Return on Assets
-16.79%
Gross Margin
0.00%
Operating Margin
-5050.92%
Profit Margin
6177.42%
Current Ratio
28.87
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-9.39M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-8.53M

Market Snapshot

About

Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating development of life-transforming therapies for patients with severe and rare diseases. The company focuses on inhibiting harmful immune responses underlying disease, replacing missing or deficient enzymes or proteins, and modulating dysregulated immune responses. Rallybio has a pipeline of product candidates addressing complement-mediated diseases and genetic disorders.